
Yes, this one is real. In 2016 Kristopher "Kris" Boesen, a 20-year-old from Bakersfield, California, who had been left paralysed from the neck down by a car crash, regained the use of his arms and hands after doctors at Keck Hospital of USC injected 10 million lab-grown cells into his damaged spinal cord. Three months later he could feed himself, use a phone, sign his name and drive a motorised wheelchair.
It is a genuinely hopeful story, but it is also easy to misread. Kris was not cured, he did not walk again, and the treatment he received was an early-stage clinical trial, not a therapy anyone can buy. Here is what happened, how the cells are thought to work, what the wider trial showed, and how to tell real stem cell research from the clinics that sell false hope.
The crash and the decision to join a trial
On 6 March 2016, a few weeks short of his 21st birthday, Kris was driving on a wet road when his car fishtailed, struck a tree and hit a telephone pole. The impact injured his spine in the neck, the cervical region, where damage affects the arms and hands as well as everything below.
His parents were told that their son might never move below the neck again. Like many people with high spinal injuries, he faced a future of full-time care, with surgery able to stabilise his spine but not to bring back lost nerve function.
Then the family heard about a study at USC. It was testing a cell product called AST-OPC1, made by Asterias Biotherapeutics of Fremont, California, in people with recent, severe neck injuries. There was no promise that it would help, and there were surgical risks. Kris and his family decided the chance was worth taking.
What doctors did in April 2016

In early April 2016 a surgical team led by Dr Charles Liu, director of the USC Neurorestoration Center, injected 10 million AST-OPC1 cells directly into Kris's injured cervical spinal cord. The operation was done at Keck Hospital of USC in partnership with Rancho Los Amigos National Rehabilitation Center, where much of his rehabilitation took place.
Liu described the logic plainly: standard spinal surgery stabilises the spine but does very little to restore movement or sensation. The trial was asking whether adding cells could change that, potentially making the difference between permanent paralysis and the use of one's arms and hands.
What AST-OPC1 actually is
The cells were not taken from Kris's own body. They were derived from human embryonic stem cells and then coaxed in the lab into oligodendrocyte progenitor cells. In a healthy spinal cord, oligodendrocytes wrap nerve fibres in myelin, the fatty insulation that lets signals travel quickly. After an injury, many of these support cells die, and nerve fibres that survive can stop working properly.
The hope is that the transplanted cells can replace some of that lost support, produce protective factors and help surviving nerve pathways carry signals again. They are not a way of regrowing the whole cord.
How much movement Kris got back
According to USC, Kris showed the first signs of improvement about two weeks after surgery and went home nearly six weeks after the operation. By 90 days his motor function had improved by up to two spinal cord levels.
That phrase sounds technical, but in daily life it is huge. Each level of the cervical cord controls particular muscles. Gaining two levels in the neck can mean the difference between depending on others for almost everything and being able to eat, text, write and steer a powered chair yourself. Those were exactly the skills Kris regained.

Kris put it simply when USC reported his progress: All I've wanted from the beginning was a fighting chance
. He also said that if walking ever became possible, he wanted to try.
It is worth being clear about the limits. He remained a wheelchair user, and his doctors made no promise of further gains. Some recovery after spinal injury also happens naturally in the first months, which is one reason a single patient's story cannot prove a treatment works.
What the wider SCiStar trial showed
Kris was one patient in SCiStar, a Phase 1/2a trial of rising doses of AST-OPC1 run at six US sites and partly funded by the California Institute for Regenerative Medicine. Phase 1/2 trials are mainly designed to check safety and look for early signals of benefit.
In September 2016 the company presented interim results at the International Spinal Cord Society meeting in Vienna. In the 10-million-cell group, all four patients who had reached 90 days had improved by at least one motor level on at least one side, and two of the four by two levels. No serious side effects were linked to the cells, the injection or the low-dose drug used to stop the immune system attacking them.
Those numbers are encouraging but small. The study had no control group, the data were reported by the company, and they were not yet peer reviewed. Asterias was later absorbed into BioTime, now Lineage Cell Therapeutics, which continues to develop the cells under the name OPC1.
Was Kris the first person ever treated this way?
No. The headline that circulated online called him the first paralysed man treated with stem cells, but that is not accurate. The same family of cells had already been tested by Geron, whose embryonic-stem-cell spinal cord trial won FDA clearance in January 2009 and was discontinued in November 2011 for business reasons. Kris's case drew attention because his improvement was so visible.
Stem cells and paralysis: myths and realities
Stories like this one are often shared with claims that stem cells now cure paralysis. The reality is more careful:
- Myth: stem cells can rebuild a severed spinal cord. Current trials aim for partial gains in specific muscles, usually measured in levels or motor scores.
- Myth: any "stem cell clinic" offers the same thing. Products used in regulated trials are manufactured, dosed and monitored under strict rules. Many private clinics inject poorly characterised cells with no evidence and real risks, including infection and tumours.
- Reality: timing matters. SCiStar treated people in the subacute window, roughly two to four weeks after injury. Results in people injured years ago may be very different.
- Reality: rehabilitation still matters. Intensive therapy, like the work Kris did at Rancho Los Amigos, remains central to any recovery.
If you or someone you love has a spinal injury
Families facing a new spinal cord injury often search for stories like Kris's, and it is natural to want to act fast. A few practical steps help:
- Ask the treating spinal team whether any registered clinical trials are recruiting, and check listings on ClinicalTrials.gov.
- Be wary of anyone charging large fees for stem cell injections outside a trial. The International Society for Stem Cell Research runs a public guide on how to spot unproven treatments.
- Talk to a doctor before making any decision about an experimental therapy.
Kris's recovery remains one of the best-known moments in spinal cord research, and the work it represented is still moving forward. Its real lesson is patience: careful trials, honest reporting and small, hard-won gains that change lives.
Sources: USC Today, Experimental stem cell therapy helps paralyzed man regain use of arms and hands (2016); Shepherd Center, SCiStar interim results (2016); Lineage Cell Therapeutics (Wikipedia); Geron Corporation (Wikipedia); ISSCR, About Stem Cells; first reported by The Hearty Soul.

COMMENTS